Market capitalization | $167.50m |
Enterprise Value | $162.80m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 3,256.00 |
P/S ratio (TTM) P/S ratio | 3,350.00 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | -72.51% |
Revenue (TTM) Revenue | $50.00k |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
3 Analysts have issued a Checkpoint Therapeutics, Inc. forecast:
3 Analysts have issued a Checkpoint Therapeutics, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 0.05 0.05 |
71%
71%
|
|
Gross Profit | - - |
-
|
|
EBITDA | -38 -38 |
36%
36%
|
EBIT (Operating Income) EBIT | -38 -38 |
36%
36%
|
Net Profit | -46 -46 |
14%
14%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Checkpoint Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. Its product portfolio include CK-301, CK-101, CK-103, and CK-302. The company was founded on November 10, 2014 and is headquartered in New York, NY.
Head office | United States |
CEO | James Oliviero |
Employees | 23 |
Founded | 2014 |
Website | www.checkpointtx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.